Daily Archives: July 17, 2022

NEWARK, Calif., July 12, 2022 /PRNewswire/ --Ultima Genomics, Inc. (the Company) has signed an agreement with Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) to further advance Ultima Genomics' sequencing architecture. Under the terms of the agreement, Regeneron will collaborate with Ultima on the development and testing of Ultima's second-generation sequencing platform, which will build upon the advances of the Company's first instrument, the UG100anticipated to launch in 2023. In conjunction with the agreement, Regeneron, who is currently part of the early access program for the UG100, will also become an investor in Ultima. The primary objective of the collaboration between Ultima and Regeneron is to enable affordable high-throughput sequencing for large-scale genomic analysis and to accelerate insights and discoveries that will profoundly impact life sciences research around the world.

"Regeneron and Ultima share a common goal of using science to improve human health," said John Overton, Ph.D., Vice President and Chief of Sequencing and Lab Operations at the Regeneron Genetics Center (RGC). "With more than 120 active research collaborations and one of the largest whole exome sequencing reference libraries in the world, we at the RGC are keenly interested in the development of technologies that streamline the drug discovery and development process. The high cost of next-generation sequencing constrains the production of genomic information a significant bottleneck for life sciences research. With this agreement, we hope to contribute to an affordable and scalable solution that enables the rapid advance of genomic sciences, and in turn, important medicines for patients in need."

"We founded Ultima Genomics with the mission to continuously drive the scale of genomic information," said Gilad Almogy, Ultima Genomics' founder and Chief Executive Officer."While we will soon be launching our first instrument platform, the UG100, we are already hard at work developing our second platform to provide even lower cost and greater scale. We are excited to collaborate with Regeneron on this project and look forward to providing tools with the ever-increasing capability to our customers. Throughout our development, we have relied on, and are grateful for, the support, trust, and relationship with collaborators such as Regeneron, all of which are among the leading sequencers in the world."

Over the last five years, Ultima Genomics has developed a fundamentally new sequencing architecture designed to scale beyond conventional approaches and enable sequencing at a fraction of the cost of other commercially available technologies. The new architecture includes completely different approaches to flow cell engineering, sequencing chemistry, and machine learning.Ultima is currently in an early access program for the UG100, its first high throughput NGS instrument using the new technology architecture. The second-generation instrument will further increase the scale of genomic data and reduce sequencing costs beyond the first instrument. The timing of development and commercial availability of the Company's second instrument is not yet disclosed.

About Ultima Genomics

Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth, and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit http://www.ultimagenomics.com

Media inquiries: [emailprotected]

SOURCE Ultima Genomics

Read the rest here:
Ultima Genomics signs development agreement with Regeneron aimed at driving the scale of genomic information for drug discovery and development - PR...

SkyQuest Technology Consulting Pvt. Ltd.

Global next generation sequencing market was valued at $10.28 billion in 2021, and it is expected to reach a value of $33.73 billion by 2028, at a CAGR of 18.50% over the forecast period (20222028).

Westford, USA, July 13, 2022 (GLOBE NEWSWIRE) -- Next generation sequencing (NGS) is a game-changing technology that is revolutionizing how we study and understand biology. NGS allows us to sequence vast amounts of DNA or RNA much faster and more cheaply than ever before, making it possible to generate unprecedented amounts of data about the genomes of organisms. The demand for NGS services in the global next generation sequencing market has been growing rapidly in recent years, as the technology has become more affordable and accessible. A wide variety of scientific disciplines are now using NGS, including human genomics, cancer research, microbiology, evolutionary biology, agriculture, and many others. The number of publications featuring NGS data has also been increasing rapidly in recent years.

One of the key factors driving the growth of the next generation sequencing market is the ongoing need for better methods for diagnosing and treating diseases. For example, NGS can be used to detect genetic variations that may be associated with disease risk. It can also be used to identify novel drug targets and develop personalized medicines. In addition, NGS is playing an increasingly important role in basic research as scientists strive to understand the complexities of genome function.

Next Generation Sequencing: A Magic Wand for Early Diagnosis of Cancer

The global prevalence of cancer is alarmingly high, with an estimated 17 million new cases and 10 million deaths in 2020 alone. The World Health Organization (WHO) predicts that these figures will rise to 27 million new cases and 16.3 million deaths by 2040 if current trends continue. Early detection of cancer through screening programs is one of the most effective ways to reduce the burden of this disease, as it can lead to earlier diagnosis and treatment, which can improve survival rates significantly. Apart from this, more than 400,000 children develop cancer every year.

Story continues

The next generation of sequencing technology is often heralded as a magic wand for the early diagnosis of cancer. This is because it has the potential to provide rapid and accurate identification of tumors at an early stage, when they are most treatable. Next generation sequencing (NGS) technology intervenes at the level of DNA, providing information on genetic variation within a tumor. This can be used to detect early-stage cancers that may not yet have developed symptoms or detectable changes at the cellular level. The Global next generation sequencing market is also gaining demand for monitoring the progression of a cancer, and to assess how well treatments are working.

There are several reasons why NGS is seen as such a powerful tool in cancer diagnosis and treatment. First, it is extremely sensitive and can detect very small amounts of DNA from a tumor. Second, it can rapidly generate large amounts of data, which can be used to identify even rare mutations that may be associated with cancer. Finally, NGS is relatively simple and inexpensive to perform, making it widely accessible across the global next generation sequencing market from almost all strata of society, especially in developed market like the US, the UK, and Germany, among others. Despite all these advantages, there are still some challenges associated with the use of NGS in cancer diagnosis and treatment. While NGS can identify DNA alterations that may be associated with cancer.

Get sample copy of this report:

https://skyquestt.com/sample-request/next-generation-sequencing-market

Next Generation Sequencing is Becoming Popular among Parents to Check Inborn Errors

As more and more parents learn about the benefits of next generation sequencing (NGS), its popularity is growing as a tool to check for inborn errors. NGS can provide a more comprehensive picture of a child's health, allowing parents to catch potential problems early and get their children the treatment they need. While NGS is not yet perfect, it is becoming more reliable and affordable as technology improves. As more parents learn about its potential, next generation sequencing market is likely to become even more popular as a way to keep children healthy and catch problems early.

As the technology for DNA sequencing gets cheaper and more sophisticated, an increasing number of parents are opting to have their child's genome sequenced at birth. This is especially true for parents who have a family history of genetic diseases. Sequencing the genome of a newborn is becoming more popular as the technology gets cheaper and more sophisticated. Inborn errors of metabolism are a group of rare genetic disorders that can cause serious health problems. Many of these disorders in the global next generation sequencing market are difficult to diagnose, and they often go undetected until something goes wrong.

According to the National Institutes of Health, about 25% of all live births in the United States each year are affected by at least one hereditary disease. However, the prevalence of these disorders varies widely, depending on the specific condition. For example, conditions like cystic fibrosis and sickle cell disease are relatively common, while others like Huntingtons disease are much rarer.

There are many different types of hereditary diseases, and they can affect any organ or system in the body. Some of the more common conditions include heart defects, respiratory problems, mental retardation, metabolic disorders, and cancer. Many of these disorders are life-threatening or cause significant disability, so it is important to be aware if any family members who have been affected by them. As a result, people are increasingly focusing getting their genome sequenced to know if they are carrying any gene that can lead to cancer.

With advancement in the next generation sequencing market, parents can now choose to have their child's genome sequenced at birth. This gives them the ability to catch these disorders early and start treatment immediately. It also allows them to make informed decisions about their child's future health. Although the cost of sequencing a genome is still relatively high, it is dropping rapidly. And as the technology continues to improve, it is expected that more parents will choose to have their child's genome sequenced at birth.

Food Industry to Offer Lucrative Opportunity for Next Generation Sequencing Market as Safety Concern Rises

The application of next generation sequencing in food safety and quality is an area of great interest and promise. The use of next generation sequencing technologies has the potential to revolutionize how we monitor food safety and quality. By providing rapid and high-throughput sequence data, next generation sequencing can be used to detect pathogens and other microorganisms in food more quickly and accurately than ever before. Additionally, the application of next generation sequencing can help us to better understand the genetic basis of food spoilage and contamination.

Growing concern about food safety has led to stricter quality control measures in the food industry. In particular, there is a greater focus on ensuring that food products are free from contaminants and meet safety standards, which is offering a lucrative opportunity for the players active in the next generation sequencing market to make most out of it. To this end, food manufacturers are increasingly adopting quality management systems such as Hazard Analysis and Critical Control Points (HACCP). These systems help to identify and control potential hazards at all stages of the food production process, from raw materials to finished products.

There are many different applications of next generation sequencing market in food safety and quality. One example is the use of next generation sequencing for pathogen detection. Pathogens are a major cause of foodborne illness, and traditional methods for detecting them often have low sensitivity or take too long to provide results. However, next generation sequencing can be used to rapidly detect pathogens in food samples with high accuracy. This information can then be used to taking steps to prevent outbreaks before they occur. In addition to pathogen detection, another important application of next generation sequencing is monitoring antibiotic resistance in bacteria present in food items. Antibiotic resistance is a growing public health concern, as it makes infections harder to treat and increases the risk of potentially deadly superbugs infection.

Browse summary of the report and Complete Table of Contents (ToC):

https://skyquestt.com/report/next-generation-sequencing-market

AI and Accelerated Computing to Bring Down the Cost of Next Generation Sequencing to Less Than $300

AI and accelerated computing are already enabling a wide range of new applications in genomics. One such application is next generation sequencing (NGS), which is used to determine the order of nucleotides in DNA. NGS is currently used for a variety of purposes, including diagnosing genetic diseases, determining ancestry, and predicting drug response in the global next generation sequencing market. The cost of NGS has fallen dramatically in recent years, from $5.6 billion per genome in 2001 to less than $1,000 today. However, there is still room for further improvement.

AI and accelerated computing can help bring down the cost of NGS by making it more efficient. For example, AI can be used to streamline the process of sequence alignment, which is often the most time-consuming and computationally intensive step in NGS. In addition, accelerated computing can be used to speed up other parts of the NGS process, such as variant calling and read mapping. The combination of AI and accelerated computing has the potential to reduce the cost of NGS even further, to less than $300 per genome. This would make it affordable for many more people to access this important technology.

Top 10 Biologics Companies in the US Raised Over 1.65 billion in 2021, but Ultima Genomics took the Larger Piece of Pie

These companies in the global next generation sequencing market are working on developing new treatments and cures for a variety of diseases and conditions. Some of the diseases that they are targeting include cancer, Alzheimers disease, Parkinsons disease, and multiple sclerosis. The amount of money that these companies have raised shows how important it is to find new treatments for these diseases. The hope is that with this additional funding, these companies will be able to make even more progress in developing new therapies and cures. In May 2022, the company managed to raise $600 million through private equity. The company is planning to use this funding to bring down the NGS to $100 in the years to come. Apart from this, Kriya Therapeutics, Moma Therapeutics, and Aspen Neuroscience raised around $270 million, and 150 million, $147.5 million, respectively. All three of these companies are working on cutting-edge therapies that have the potential to change the lives of patients suffering from these devastating diseases. Apart from this, these company are holding major market share as they have established themselves in the market.

It is clear that biologics research is an area where there is a lot of interest and investment is coming in the global next generation sequencing market. This is good news for patients who are waiting for new treatments and cures. With more funding available, these top companies should be able to make even more progress in finding new ways to treat.

Ultima Genomics is a new biotech company that is working on cutting the cost of sequencing the human genome. Theyve created a powerful technology called named Triple X that adjusts itself by integrating new data and machine learning to bring down the cost. The first use for this companys pitch will be whole-genome sequencing, which can also be applied to other approaches like single-cell and methylation sequencing.

Speak to Analyst for your custom requirements:

https://skyquestt.com/speak-with-analyst/next-generation-sequencing-market

Key Vendors in Next Generation Sequencing Market

PerkinElmer Inc. (US)

BGI Group (China)

Agilent Technologies Inc. (US)

Eurofins Scientific SE (Luxembourg)

Pacific Biosciences of California Inc. (US)

Oxford Nanopore Technologies (UK)

QIAGEN NV (Netherlands)

F. Hoffmann-La Roche AG (Switzerland)

GENEWIZ Inc. (US)

Psomagen, Inc. (South Korea)

10x Genomics Inc. (US)

Takara Bio (Japan)

Zymo Research (US)

NuGen Technologies (US)

Hamilton Company (US)

Beckman Coulter (US)

Becton, Dickinson, and Company (US)

Lucigen Corporation (US)

Novogene Co., Ltd. (China)

Related Reports in SkyQuests Library:

Global Medical Tourism Market

Global Home Healthcare Market

Global Consumer Healthcare Market

Global Healthcare Consulting Services Market

Global 3D Cell Culture Market

About Us:

SkyQuest Technologyis leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.

Address:

1 Apache Way, Westford, Massachusetts 01886

Phone:

USA (+1) 617-230-0741

Email:sales@skyquestt.com

LinkedInFacebookTwitter

Here is the original post:
Next Generation Sequencing Market to Reach $33.73 billion By 2028 Thanks to Increased Attention Early Disease Diagnosis and High Prevalence of Cancer...

Global Whole Genome Amplification Market Forecast 2022-2028, key research on the industry condition of the Whole Genome Amplification is presented together with the best content, definition, expert opinion, SWOT analysis, meaning, and newest development around the world. The Whole Genome Amplification research includes information on industry size, sales, price, revenue, market share, gross margin, growth rate, and cross structure. The study examines the profit made from the sale of this report and technologies across a number of segments, as well as provides a comprehensive table of contents on the Market.

Get Latest Sample PDF Report: https://www.worldwidemarketreports.com/sample/815388

Segmentation based on Key players

Sigma-Aldrich QIAGEN NV GE Healthcare LGC Group

Segmentation based on Type

Single Cell WGA Kit Complete WGA Kit WGA Reamplification Kit WGA & Chip DNA Kit Others

Segmentation based on Application

Drug Discovery & Development Disease Diagnosis Agriculture & Veterinary Research Forensics Others

Get Latest Sample PDF Report: https://www.worldwidemarketreports.com/sample/815388

The research examines the Whole Genome Amplification market in-depth, focusing on several factors such as drivers, restraints, opportunities, and threats. Before investing, stakeholders can use this information to make informed judgments. It also enables you to conduct useful competitive research in order to generate marketing ideas for your products. When it comes to customer happiness, its critical to have a clear understanding of whats going on in the market. The general market scenario is accurately described in this research.

Impact Of Covid-19 on Whole Genome Amplification :

COVID-19 is an unprecedented global public health crisis that has impacted practically every business, and its long-term repercussions are expected to have an influence on industry growth during the forecast period. Our continuous study is enhancing our research approach to guarantee that fundamental COVID-19 concerns and potential solutions are included. The research examines COVID-19 in light of changes in consumer behavior and demand, purchasing patterns, supply chain re-routing, market dynamics, and government involvement. The updated study considers the impact of COVID-19 on the market and provides insights, analysis, projections, and forecasts.

Tap Here to See How This Whole Genome Amplification Report Addresses COVID-19 Impact: https://www.worldwidemarketreports.com/covidimpact/815388

The following geographic segments are covered in the report:

The Whole Genome Amplification report provides information on the market area, which is divided into sub-regions and countries/regions. In addition to the market share in each country and sub-region, this chapter in this report also contains information on profit opportunities. This chapter of the report mentions the market share and growth rate for each region, country, and sub-region during the estimated period.

North America includes the United States, Canada, and Mexico

Europe includes Germany, France, UK, Italy, Spain

South America includes Colombia, Argentina, Nigeria, and Chile

The Asia Pacific includes Japan, China, Korea, India, Saudi Arabia, and Southeast Asia

When analyzing the key market participants, what aspects are taken into account?

Buy this Research Report:https://www.worldwidemarketreports.com/buy/815388

Key Questions Answered in the Report:

Contact Us :

Mr. ShahWorldwide Market Reports,Tel: U.S. +1-415-871-0703U.K. +44-203-289-4040Japan +81-50-5539-1737Email: [emailprotected]Website: https://www.worldwidemarketreports.com/

Read this article:
Whole Genome Amplification Market Report: One Research Solution Reveal Everything You Need to Know About Key Players: Sigma-Aldrich, QIAGEN NV, GE...

The discoveries show that ancient DNA can be recovered from Pompeiian human bones, providing new insight into this historic communitys genetic history and lifestyles.

Research that was recently published in Scientific Reports presents the first human genome that has been successfully sequenced from a person who passed away in Pompeii, Italy, after Mount Vesuvius explosion in the year 79 CE. Only little segments of mitochondrial DNA from Pompeiian human and animal remains have been sequenced up to this point.

The DNA of two peoples bones that were discovered in Pompeiis House of the Craftsman was studied and extracted by Gabriele Scorrano and colleagues. The bones length, form, and structure revealed that one pair belonged to a male who was between 35 and 40 years old when he passed away, while the other set belonged to a femalewho was over 50. The authors were able to extract and sequence ancient DNA from both people, but since the sequences from the females bones had gaps in them, they could only sequence the entire genome from the males remains.

The male subjects DNA was compared to 1,030 ancient and 471 current western Eurasian subjects, and it was found that the male subjects DNA was most comparable to that of modern central Italians and other people who resided in Italy during the Roman Imperial era. However, studies of the males Y chromosome and mitochondrial DNA revealed sets of genes that are often prevalent in Sardinian people but not in other people who resided in Italy during the Roman Imperial era. This shows that the Italian Peninsula may have seen high levels of genetic diversity at the time.

Additional analyses of the male individuals skeleton and DNA identified lesions in one of the vertebrae and DNA sequences that are commonly found in Mycobacterium, the group of bacteria that the tuberculosis-causing bacteria Mycobacterium tuberculosis belongs to. This suggests that the individual may have been affected by tuberculosis prior to his death.

The authors speculate that it may have been possible to successfully recover ancient DNA from the male individuals remains as pyroclastic materials released during the eruption may have provided protection from DNA-degrading environmental factors, such as atmospheric oxygen. The findings demonstrate the possibility to retrieve ancient DNA from Pompeiian human remains and provide further insight into the genetic history and lives of this population, they add.

Reference: Bioarchaeological and palaeogenomic portrait of two Pompeians that died during the eruption of Vesuvius in 79 AD by Gabriele Scorrano, Serena Viva, Thomaz Pinotti, Pier Francesco Fabbri, Olga Rickards, and Fabio Macciardi, 26 May 2022, Scientific Reports.DOI: 10.1038/s41598-022-10899-1

Read the rest here:
Scientists Have Sequenced the DNA of a 2000-Year-Old Human From Pompeii - SciTechDaily

Covered in sheep fluids, John Gorzynski climbed the stairs to his Wales apartment, exhausted. It was springtime, 2016, which for a veterinarian in rural areas of the United Kingdom means only one thing: newborn lambs, and a lot of them.

Gorzynski was his town's on-call vet. In one night, he'd performed five cesarean sections on sheep struggling to birth their lambs, and it was now 3 a.m. But before he could reach the door to his flat and have a good shower, his phone rang.

Another lamb in peril -- back to work.

"In that moment, I knew I needed a change," said Gorzynski, DVM, PhD, who is now a postdoctoral scholar at Stanford Medicine. "That lifestyle was just not sustainable for me."

He yearned to return to a research lab, where his work schedule wouldn't hinge on laboring farm animals.

The desire set Gorzynski on a path that, in 2016, brought him to the Stanford Medicine lab of biomedical data scientist and geneticist Euan Ashley, MB ChB, DPhil. During his time at Stanford, he and others have devised record-setting genome sequencing techniques, researched heart disease in great apes and deciphered genetic cardiovascular conundrums in humans.

Gorzynski grew up on a small organic farm in New York, diligently cultivated by his father. The upbringing, he said, fostered his love of animals and the outdoors. "As a kid I'd just sit up in the orchard trees, picking and snacking on cherries, apples and peaches," he said. "It's where my love of nature and animals originated."

Eventually, though, Gorzynski deviated from the family business when he chose a career in medicine. Everything was on track when he was an undergraduate at St John's University in New York -- but then he witnessed his first autopsy. "It totally put me off being a human doctor," he recalled.

His passion for medicine persisted, however, so after graduating in 2007, Gorzynski explored other options. "I hadn't considered veterinary medicine before that -- but it suddenly seemed like a clear choice," he said.

Lured by its metropolitan location and solid research reputation, Gorzynski enrolled at the University of London's Royal Veterinary College for veterinary training and joined the lab of professor of veterinary cardiology Adrian Boswood, VetMB, who researched genetic causes of cardiovascular disease in great apes, a group of primates that include chimpanzees, gorillas and bonobos.

During his time at the lab, two chimpanzees died of sudden cardiac failure at the London Zoo. Both were around 16 or 17 years old, some 35 years shy of the average lifespan of a chimpanzee in captivity. And here was the kicker: They were related. "It made me wonder if there might be a genetic component at play," Gorzynski said.

In investigating the cause of the apes' deaths, Gorzynski and others found anatomical anomalies that resembled a cardiovascular disease in humans: arrhythmogenic right ventricular cardiomyopathy, or ARVC, which interferes with proper heart rhythms. That can lead to insufficient blood supply to organs and, ultimately, sudden death.

In humans, at least 50% of this type of cardiomyopathy is due to a genetic defect. Because humans and chimpanzees share a whopping 98% of their DNA, it stands to reason that whatever we know about humans could apply to chimpanzees, and vice versa.

The disease is believed to arise from a mutation in genes associated with a structure in heart muscle cells. With DNA from the deceased chimpanzees, Gorzynski and others dug more deeply into whether the primates harbored mutations in the key genes known to cause ARVC in humans.

Expanding the research to include the rest of the zoo's chimpanzees, the researchers monitored their heart function and examined their DNA to determine whether any heart abnormalities were genetic. Eventually, using samples from wild chimpanzees from the Jane Goodall Institute, the team also investigated the incidence of ARVC in apes in their natural habitats to compare with those in captivity.

In the end, the research was inconclusive.

"We found genetic differences between captive and wild chimpanzees, but our data wasn't granular enough to see if those variants were actually causative of the disease," Gorzynski said. The technology just wasn't advanced enough. His research hit a standstill.

After his veterinary training wrapped up, Gorzynski practiced animal medicine in Four Crosses, Powys, Wales as a mixed-animal surgeon for the next 2 years.

"I just decided, 'I'm going to live my best James Herriot life,'" he said, referring to the pen name of a veterinary surgeon who chronicled his work in the book All Creatures Great and Small and its sequels. "I saw birds, dogs, cats, ferrets, sheep, cows, horses -- it was great, and fun, but it was exhausting."

After the fateful night of five sheep C-sections, when Gorzynski made up his mind to return to ape research, he began seeking graduate programs. Ashley's work -- everything from studying the biology of endurance athletes to deciphering mystery diseases -- caught Gorzynski's interest. And the intrigue went both ways.

"I remember sending him a note, and Euan responded and said, 'You know, I've been waiting for someone like you -- I have this really interesting project,'" Gorzynski said.

That project focused on Koko, a famed gorilla born in the San Francisco Zoo who wowed the world with her sign language skills. Gorzynski returned to the United States to start research as a Stanford Medicine graduate student working with Ashley, a professor of genetics, of biomedical data science and of cardiovascular medicine.

Stanford's cardiovascular team was monitoring Koko, along with other great apes at a nearby preserve where Koko had lived, for structural heart disease and saw signs of a cardiovascular condition. Powered by new, more advanced genome sequencing, Gorzynski hoped to determine if there were key genes that spurred Koko's heart ailments. Sadly, Koko died in June, 2018 of unrelated causes.

To broaden the research, Gorzynski reconnected with his collaborators at the Jane Goodall Institute to share genomic data and findings. (The specimens Gorzynski sequences are collected after a great ape dies of natural causes in a sanctuary in the Republic of the Congo that the institute supports.)

When that research was paused in 2020 by COVID-19-related travel restrictions, Gorzynski had to find new ways to round out his degree. The detour resulted in him contributing to research that set a new world record: the fastest genome sequencing technique. The process, from sequencing the genome of a patient to providing clinical information, took several hours, a big improvement from the typical timing of a few weeks.

Now that travel restrictions have loosened, Gorzynski has resumed his ape-related studies. "What we learn from our studies could inform heart disease in humans but, honestly, that's not why I'm doing this research," Gorzynski said. "My focus is the health and well-being of the animals, and my hope is that this research can teach us how to better maintain a healthy population of wild great apes."

Photo by Savory

Continue reading here:
Unconventional paths: Gorzynski and the great apes - Scope

DUBLIN--(BUSINESS WIRE)--The "Global Blockchain Market, By Component, By Type, By Application, & By Region - Forecast and Analysis 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.

The Global Blockchain Market was valued at USD 4.56 Billion in 2021, and it is expected to reach a value of USD 117.77 Billion by 2028, at a CAGR of more than 59.12% over the forecast period (2022 - 2028).

The global blockchain market is rapidly growing and is expected to continue to do so in the future years, due to the expanding number of innovations and consumer awareness of the benefits of employing blockchain technology is expected to propel the industry forward in the near future. The key aspects driving the growth of the global blockchain market include the adoption of blockchain technology across BFSI, healthcare, media and entertainment, and many others.

Wide acceptance of blockchain solutions for payment, digital identities, and smart contracts are also among some of the prospects that drive the industry growth during the forecast period. The increased venture capital investing in blockchain technology startups can also be attributed to the market's growth. Blockchain technology witnessed significant growth after the advent of Bitcoin, and it is now being used by various financial institutions for transactions.

In the last two to three years, blockchain technology solutions have gained in popularity for a variety of commercial applications, including payments, exchanges, documentation, and many others. Many startups such as Blockpoint, Auxesis Group, Symbiont, SpinSys, Bitfury, Neufund, Fetch.AI, Confirm, Genomes, QubiTech, and CiveQ among others have entered the market and begun developing blockchain-based solutions

Aspects covered in this report

The global blockchain market is segmented on the basis of component, type and application. Based on the component, the market is segmented as platform and services. Based on the type, the market is segmented as public, private, and hybrid. Whereas, based on the applications, the market is segmented as Food & Agriculture, Transportation & Logistics, Manufacturing, Energy & Utilities, Healthcare & Life Sciences, Media & Entertainment, BFSI, Retail & E-Commerce, IT & Telecom, and Others.

Driver

Restraint

Key Market Trends

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/e2mwxc

Read more from the original source:
Global Blockchain Market Report (2022 to 2028) - Featuring Genomes, QubiTech and CiveQ Among Others - ResearchAndMarkets.com - Business Wire